Virpax Pharmaceuticals, Inc. (VRPX)
VRPX moved a median of 0.00% 30 minutes after news, and -1.43% by the close. How VRPX actually reacts to news — the realized, point-in-time move the market made, measured across 143 labeled events over the last three years with zero look-ahead.
VRPX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 125 |
| 30-min | 0.00% | 49% | 141 |
| 60-min | -1.01% | 34% | 143 |
| to close | -1.43% | 43% | 143 |
| Middle 50% of VRPX reactions | -3.43% to +3.19% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 143 |
Half of all Virpax Pharmaceuticals, Inc. news events land between -3.43% and +3.19% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VRPX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VRPX's baseline. Nothing else.
Recent VRPX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Virpax Pharmaceuticals, For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -35.18% | -38.01% | |
| Form 8-K/A Virpax Pharmaceuticals, For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -25.00% | +75.00% | |
| Form S-1/A Virpax Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +0.54% | -13.44% | |
| Form 8-K Virpax Pharmaceuticals, For: Mar 21 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | -5.83% | |
| Virpax Pharmaceuticals Announces Reverse Stock Split | Press release | Business Wire | -8.81% | -17.17% | |
| Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND | Press release | Business Wire | -8.81% | -17.17% | |
| Form S-1 Virpax Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | -1.54% | +0.00% | |
| Virpax Looking to Use MET to Develop Intranasal COVID Vaccine | Press release | Business Wire | -1.05% | -2.76% | |
| Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS | Press release | Business Wire | -0.05% | -1.58% | |
| Form 10-K Virpax Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.16% | +0.00% | |
| Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology | Press release | Business Wire | -0.21% | -9.43% | |
| Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study | Press release | Business Wire | -4.94% | -27.81% | |
| Form 8-K Virpax Pharmaceuticals, For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.81% | |
| Form 8-K Virpax Pharmaceuticals, For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.97% | |
| Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference | Press release | Business Wire | +1.08% | +1.76% | |
| Form 8-K Virpax Pharmaceuticals, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | +1.08% | +1.76% | |
| Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering | Press release | GlobeNewswire | -2.29% | -2.29% | |
| Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | Business Wire | +1.35% | -4.27% | |
| Form EFFECT Virpax Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -3.48% | +15.28% | |
| Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | Business Wire | -3.48% | +15.28% | |
| Form S-1/A Virpax Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | -4.43% | -3.61% | |
| Form 8-K Virpax Pharmaceuticals, For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | +5.50% | -5.08% | |
| Form S-1/A Virpax Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +5.50% | -5.08% | |
| Form 8-K Virpax Pharmaceuticals, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | -5.06% | |
| Form 8-K Virpax Pharmaceuticals, For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | +2.15% | +2.12% | |
| Form S-1 Virpax Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +2.15% | +2.12% | |
| Form 8-K Virpax Pharmaceuticals, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +2.90% | +2.06% | |
| Form 8-K Virpax Pharmaceuticals, For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | -2.87% | -7.08% | |
| Form DEF 14A Virpax Pharmaceuticals, For: Dec 09 | SEC filing · Form DEF | SEC EDGAR | +1.81% | +1.97% | |
| Form 8-K Virpax Pharmaceuticals, For: Nov 27 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | +2.47% | |
| Form 8-K Virpax Pharmaceuticals, For: Nov 25 | SEC filing · Form 8-K | SEC EDGAR | +4.44% | +2.89% | |
| Form 8-K Virpax Pharmaceuticals, For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | -7.11% | -5.78% | |
| Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™ | Press release | Business Wire | +13.59% | -29.71% | |
| Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative | Press release | Business Wire | +13.59% | -29.71% | |
| Form 8-K Virpax Pharmaceuticals, For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -13.10% | |
| Form PRE 14A Virpax Pharmaceuticals, For: Nov 20 | SEC filing · Form PRE | SEC EDGAR | +4.13% | -1.47% | |
| Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering | Press release | GlobeNewswire | -4.03% | +8.20% | |
| Form 8-K Virpax Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -2.07% | +1.30% | |
| Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | Business Wire | -2.07% | +1.30% | |
| Form 10-Q Virpax Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.26% | -6.94% | |
| Form EFFECT Virpax Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +8.79% | |
| Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | Business Wire | +0.00% | +8.79% | |
| Form S-1/A Virpax Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | -1.30% | -1.43% | |
| Form S-1/A Virpax Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | -1.51% | -2.92% | |
| Form S-1/A Virpax Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +6.76% | +6.12% | |
| Form 10-K/A Virpax Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -3.09% | |
| Form 8-K/A Virpax Pharmaceuticals, For: Oct 04 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | -4.17% | |
| Form 8-K Virpax Pharmaceuticals, For: Oct 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.40% | |
| Form 8-K Virpax Pharmaceuticals, For: Oct 03 | SEC filing · Form 8-K | SEC EDGAR | -4.98% | -25.25% | |
| Form 8-K Virpax Pharmaceuticals, For: Sep 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.03% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VRPX section they belong to.
Where else VRPX is measured.
VRPX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Virpax Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled VRPX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 143 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of VRPX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VRPX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.